Vertex Pharmaceuticals Incorporated Stock Analysis & AI Score
Vertex Pharmaceuticals Incorporated (VRTX) has an ST Score of 55.5 (B-), driven by its Profitability (A+) and held back by its Valuation (F). Analysts rate it Buy with a $573.50 price target (+11.4% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
AI Daily Briefing
Analysis by AIVRTX Stock Price History
VRTX Technical Indicators
FMPEarnings Surprises
Analyst Forecast
Revenue Mix
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Analyst Price Target
ESG Score
VRTX Latest Stock News
ST Score
Vertex Pharmaceuticals Incorporated (VRTX) has an ST Score of 55.5 (B-), driven by its Profitability (A+) and held back by its Valuation (F). Analysts rate it Buy with a $573.50 price target (+11.4% upside).
- Strongest
- ProfitabilityA+
- Weakest
- ValuationF
All factor grades
- ProfitabilityA+
- SentimentA+
- MomentumA
- ForecastC+
- GrowthC
- Financial StrengthD
- ValuationF
- Piotroski5/9
Press Releases
Company Contact Details
VRTX stock: frequently asked questions
What is VRTX's ST Score?
Vertex Pharmaceuticals Incorporated (VRTX) has an ST Score of 55.5 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is VRTX a buy, hold, or sell?
Analysts rate VRTX a Buy, with a price target of $573.50 (+11.4% vs the current price). Our ST Score grades it B- (55.5/100). The ST Score is a data-driven signal, not a recommendation.
What are VRTX's factor grades?
Valuation F, Profitability A+, Financial Strength D, Momentum A, Growth C, Forecast C+, Sentiment A+.
What is VRTX's valuation grade?
Vertex Pharmaceuticals Incorporated (VRTX) earns a valuation grade of F, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is VRTX's growth grade?
Vertex Pharmaceuticals Incorporated (VRTX) earns a growth grade of C, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is VRTX's profitability grade?
Vertex Pharmaceuticals Incorporated (VRTX) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is VRTX's financial strength grade?
Vertex Pharmaceuticals Incorporated (VRTX) earns a financial strength grade of D, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for VRTX?
The average analyst price target for Vertex Pharmaceuticals Incorporated (VRTX) is $573.50 from 56 analysts, which is +11.4% versus the recent price of $514.65.
What is VRTX's Piotroski score?
Vertex Pharmaceuticals Incorporated (VRTX) has a Piotroski F-Score of 5 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.